Plasma-derived medicines (PDMPs) are essential for some 300,000 patients across the EU who rely on these therapies every day to treat a variety of rare, chronic, and life-threatening conditions. Without these treatments, many patients would have a substantially diminished quality of life, and some may not survive. PDMPs are a finite resource because the manufacture of these medicines is dependent on the amounts of human plasma collected, and shortages are a big issue for the manufacturers. Thus, PDMPs are unique in a number of ways: overall value chain complexity, human-derived source material, regulations and safety procedures, manufacturing processes and costs, therapeutic value and socio-economic impact. How can we make sure the medicines find their way to the patient?

In this presentation you will learn:

• challenges the PDMPs are facing in Europe, due to the numerous patient access restrictions – and how to overcome these challenges?
• How to build better partnerships between the industry and stakeholders?
• How to meet growing demand in plasma and how can the right policy approach help?

What are the regulatory and policy constraints for PDMPs in Europe?